The phase I multicenter trial on the safety and efficacy of ABT-414 + temozolomide in patients with EGFR-amplified recurrent GBM (NCT01800695) reported that 87% of patients experienced any grade of ocular adverse events (2). This evidence concerns the gene EGFR and glioblastoma.